Novartis & Sanofi

Novartis: Novartis is a key player in the antibody therapeutics market, benefiting from the projected market growth.

Sanofi: Sanofi is a key player in the antibody therapeutics market, benefiting from the projected market growth.

Novartis: Novartis participated in the symposium, demonstrating its commitment to green chemistry and sustainable manufacturing.

Sanofi: Sanofi participated in the symposium, reflecting its interest in sustainable manufacturing technologies.

Novartis: Novartis' Leqvio is another competitor in the PCSK9 inhibitor market. Scribe's progress may affect Novartis's competitive position.

Sanofi: Sanofi participated in a concurrent private placement, purchasing 500,000 shares for $7.5 million, and has a prior $1.5 billion research collaboration with Scribe. This deepens Sanofi's strategic involvement in gene editing and cardiovascular therapies.

Novartis: Novartis is among the pharmaceutical companies that agreed to lower drug prices for United States — Medicaid and cash payers as part of the deals with the Donald Trump administration.